Cargando…

Polymer Coated Oncolytic Adenovirus to Selectively Target Hepatocellular Carcinoma Cells

Despite significant advances in chemotherapy, the overall prognosis of hepatocellular carcinoma (HCC) remains extremely poor. HCC targeting strategies were combined with the tumor cell cytotoxicity of oncolytic viruses (OVs) to develop a more efficient and selective therapeutic system. OVs were coat...

Descripción completa

Detalles Bibliográficos
Autores principales: Garofalo, Mariangela, Bellato, Federica, Magliocca, Salvatore, Malfanti, Alessio, Kuryk, Lukasz, Rinner, Beate, Negro, Samuele, Salmaso, Stefano, Caliceti, Paolo, Mastrotto, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309094/
https://www.ncbi.nlm.nih.gov/pubmed/34202714
http://dx.doi.org/10.3390/pharmaceutics13070949
_version_ 1783728440130666496
author Garofalo, Mariangela
Bellato, Federica
Magliocca, Salvatore
Malfanti, Alessio
Kuryk, Lukasz
Rinner, Beate
Negro, Samuele
Salmaso, Stefano
Caliceti, Paolo
Mastrotto, Francesca
author_facet Garofalo, Mariangela
Bellato, Federica
Magliocca, Salvatore
Malfanti, Alessio
Kuryk, Lukasz
Rinner, Beate
Negro, Samuele
Salmaso, Stefano
Caliceti, Paolo
Mastrotto, Francesca
author_sort Garofalo, Mariangela
collection PubMed
description Despite significant advances in chemotherapy, the overall prognosis of hepatocellular carcinoma (HCC) remains extremely poor. HCC targeting strategies were combined with the tumor cell cytotoxicity of oncolytic viruses (OVs) to develop a more efficient and selective therapeutic system. OVs were coated with a polygalactosyl-b-agmatyl diblock copolymer (Gal(32)-b-Agm(29)), with high affinity for the asialoglycoprotein receptor (ASGPR) expressed on the liver cell surface, exploiting the electrostatic interaction of the positively charged agmatine block with the negatively charged adenoviral capsid surface. The polymer coating altered the viral particle diameter (from 192 to 287 nm) and zeta-potential (from –24.7 to 23.3 mV) while hiding the peculiar icosahedral symmetrical OV structure, as observed by TEM. Coated OVs showed high potential therapeutic value on the human hepatoma cell line HepG2 (cytotoxicity of 72.4% ± 4.96), expressing a high level of ASGPRs, while a lower effect was attained with ASPGR-negative A549 cell line (cytotoxicity of 54.4% ± 1.59). Conversely, naked OVs showed very similar effects in both tested cell lines. Gal(32)-b-Agm(29) OV coating enhanced the infectivity and immunogenic cell death program in HepG2 cells as compared to the naked OV. This strategy provides a rationale for future studies utilizing oncolytic viruses complexed with polymers toward effective treatment of hepatocellular carcinoma.
format Online
Article
Text
id pubmed-8309094
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83090942021-07-25 Polymer Coated Oncolytic Adenovirus to Selectively Target Hepatocellular Carcinoma Cells Garofalo, Mariangela Bellato, Federica Magliocca, Salvatore Malfanti, Alessio Kuryk, Lukasz Rinner, Beate Negro, Samuele Salmaso, Stefano Caliceti, Paolo Mastrotto, Francesca Pharmaceutics Article Despite significant advances in chemotherapy, the overall prognosis of hepatocellular carcinoma (HCC) remains extremely poor. HCC targeting strategies were combined with the tumor cell cytotoxicity of oncolytic viruses (OVs) to develop a more efficient and selective therapeutic system. OVs were coated with a polygalactosyl-b-agmatyl diblock copolymer (Gal(32)-b-Agm(29)), with high affinity for the asialoglycoprotein receptor (ASGPR) expressed on the liver cell surface, exploiting the electrostatic interaction of the positively charged agmatine block with the negatively charged adenoviral capsid surface. The polymer coating altered the viral particle diameter (from 192 to 287 nm) and zeta-potential (from –24.7 to 23.3 mV) while hiding the peculiar icosahedral symmetrical OV structure, as observed by TEM. Coated OVs showed high potential therapeutic value on the human hepatoma cell line HepG2 (cytotoxicity of 72.4% ± 4.96), expressing a high level of ASGPRs, while a lower effect was attained with ASPGR-negative A549 cell line (cytotoxicity of 54.4% ± 1.59). Conversely, naked OVs showed very similar effects in both tested cell lines. Gal(32)-b-Agm(29) OV coating enhanced the infectivity and immunogenic cell death program in HepG2 cells as compared to the naked OV. This strategy provides a rationale for future studies utilizing oncolytic viruses complexed with polymers toward effective treatment of hepatocellular carcinoma. MDPI 2021-06-24 /pmc/articles/PMC8309094/ /pubmed/34202714 http://dx.doi.org/10.3390/pharmaceutics13070949 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Garofalo, Mariangela
Bellato, Federica
Magliocca, Salvatore
Malfanti, Alessio
Kuryk, Lukasz
Rinner, Beate
Negro, Samuele
Salmaso, Stefano
Caliceti, Paolo
Mastrotto, Francesca
Polymer Coated Oncolytic Adenovirus to Selectively Target Hepatocellular Carcinoma Cells
title Polymer Coated Oncolytic Adenovirus to Selectively Target Hepatocellular Carcinoma Cells
title_full Polymer Coated Oncolytic Adenovirus to Selectively Target Hepatocellular Carcinoma Cells
title_fullStr Polymer Coated Oncolytic Adenovirus to Selectively Target Hepatocellular Carcinoma Cells
title_full_unstemmed Polymer Coated Oncolytic Adenovirus to Selectively Target Hepatocellular Carcinoma Cells
title_short Polymer Coated Oncolytic Adenovirus to Selectively Target Hepatocellular Carcinoma Cells
title_sort polymer coated oncolytic adenovirus to selectively target hepatocellular carcinoma cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309094/
https://www.ncbi.nlm.nih.gov/pubmed/34202714
http://dx.doi.org/10.3390/pharmaceutics13070949
work_keys_str_mv AT garofalomariangela polymercoatedoncolyticadenovirustoselectivelytargethepatocellularcarcinomacells
AT bellatofederica polymercoatedoncolyticadenovirustoselectivelytargethepatocellularcarcinomacells
AT maglioccasalvatore polymercoatedoncolyticadenovirustoselectivelytargethepatocellularcarcinomacells
AT malfantialessio polymercoatedoncolyticadenovirustoselectivelytargethepatocellularcarcinomacells
AT kuryklukasz polymercoatedoncolyticadenovirustoselectivelytargethepatocellularcarcinomacells
AT rinnerbeate polymercoatedoncolyticadenovirustoselectivelytargethepatocellularcarcinomacells
AT negrosamuele polymercoatedoncolyticadenovirustoselectivelytargethepatocellularcarcinomacells
AT salmasostefano polymercoatedoncolyticadenovirustoselectivelytargethepatocellularcarcinomacells
AT calicetipaolo polymercoatedoncolyticadenovirustoselectivelytargethepatocellularcarcinomacells
AT mastrottofrancesca polymercoatedoncolyticadenovirustoselectivelytargethepatocellularcarcinomacells